Grifols, S.A. (GRF.MC) Stock Price

Grifols was founded in 1909 in Barcelona as a small, family-run clinical analysis laboratory. According to the history on its official website, its founder was the hematologist Josep Antoni Grifols i Roig. Today the company works in the development of plasma-derived medicines and in transfusion medicine solutions. Its shares have traded on the Spanish stock exchange since 2006, and the history also notes its entry into the IBEX 35 index in 2008 and the start of trading on NASDAQ in 2011.

The company presents its work under four headings: Biopharma, Diagnostic, Grifols Bio Supplies and healthcare solutions for hospitals. The Biopharma side develops medicines from plasma to treat chronic and rare diseases, and the page describes plasma proteins such as immunoglobulin, albumin and antithrombin. The Diagnostic side offers blood banks and hospital transfusion centres products that ensure blood compatibility and detect possible pathogens in donors. Bio Supplies provides human biological materials for pharmaceutical and diagnostic manufacturing and for research organisations.

Those following Grifols stock usually watch developments in its network of plasma donation centres, the course of the Biopharma and Diagnostic arms, announcements about new treatment candidates and the company's announcements. On the Lzzo.com Grifols page, the price of the Madrid-listed shares appears with its observation time, together with a price history chart and technical indicators.